WEST PALM BEACH, FL / ACCESSWIRE / June 3, 2019 / Ozop Surgical Corp. (OTCQB: OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery, today announced significant development progress and completion of initial testing of their novel adjustable ALIF interbody spinal implant.
Michael Chermak, CEO, OZOP Surgical commented, “We are excited to have completed initial testing for this novel device. Only through testing can we learn how to create an optimal design and develop the instrumentation to allow for an exceptional operative outcome for the surgeon and patient. Developing an infinitely adjustable ALIF implant is a challenging design goal but the end outcome will allow the surgeon to ensure segmental stability and restore sagittal balance. We are encouraged by the results of this testing and have incorporated several improvements into our next design. We look forward to completing testing for FDA submission in the near future and hope to have our approval by the end of the year”.
About the OZOP Adjustable ALIF Implant
OZOP is developing an exciting new anterior spine implant that allows the surgeon to expand it after insertion into the disc space. This allows for patient specific adjustment, reduced operating time and inventory and cost savings for the hospital. Instrumentation has been simplified and the locking mechanism eliminates the cost and time needed for anterior supplemental fixation.
